The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ultomiris (ravulizumab) to reduce protein in the urine of adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Accelerated approval allows a therapy to be marketed based on early clinical trial…
News
The approved, monthly therapy Voyxact (sibeprenlimab-szsi) can prevent kidney function worsening and kidney failure in adults with immunoglobulin A nephropathy (IgAN), according to final two-year results from a global, late-stage clinical trial. “VOYXACT delivered durable stabilization of kidney function and substantially reduced the risk of kidney failure events,…
Enrollment of people with immunoglobulin A nephropathy (IgAN) in a mid-stage clinical trial testing Jasper Therapeutics’ treatment candidate vensobafusp alfa (KP104) — designed to last longer in the body — is now complete, with interim results expected by year’s end. A so-called basket trial, the Phase 2 study (NCT05517980)…
Initial treatment with the approved oral med Filspari (sparsentan) stabilized kidney function among people with immunoglobulin A nephropathy (IgAN), according to final two-year data from a new mid-stage clinical trial testing the oral therapy. Travere Therapeutics, which markets the drug, says these results support Filspari as a…
Representatives from the American Kidney Fund (AKF) and the IgA Nephropathy Foundation joined dozens of patient advocates on Capitol Hill last week to urge lawmakers to pass a trio of bills to improve access to care for people with rare kidney diseases, such as IgA nephropathy. “By joining…
Sefaxersen, an experimental injection therapy given once monthly, reduced protein in the urine, a marker of kidney damage, in people with immunoglobulin A nephropathy (IgAN), according to new data from a Phase 3 clinical trial. The Phase 3 study, dubbed IMAgINATION (NCT05797610), is testing sefaxersen against a…
Treatment with Trutakna (atacicept-vymj) can slow the decline of kidney function in people with immunoglobulin A nephropathy (IgAN), according to the final results of a late-stage clinical trial whose data were used to secure the therapy’s conditional clearance in the U.S. Trutakna, developed by Vera Therapeutics, was…
Finerenone, an oral medication approved for diabetes-related chronic kidney disease, may reduce urine protein levels and stabilize kidney function in adults with immunoglobulin A nephropathy (IgAN). That’s according to a one-year real-world study in China, which also showed benefits among participants who were not receiving immunosuppressive therapy, as well as…
Immunoglobulin A nephropathy (IgAN) shares genetic risk factors with many cardiovascular and metabolic conditions, a study found. The findings may help explain why people with IgAN are at high risk of health complications such as heart disease, researchers said. Based on these shared genetic profiles, they identified several existing medications…
Recent Posts
- FDA approves first C5 inhibitor to reduce protein in urine for IgAN
- Monthly therapy preserves kidney function in IgAN trial, final data show
- My chronic illness is no blessing in disguise, but I know what matters now
- Early trial data on IgA nephropathy treatment expected by year’s end
- Approved IgA nephropathy med may better help kidney function